SC Engineering "3Q Cumulative 127.1 Billion... Growth in All Businesses"

SC Engineering continued its solid performance in the third quarter this year, supported by the steady growth of its core EPC (Engineering, Procurement, and Construction) business, the healthcare new business, and its subsidiary Cellontech, which operates in the bio sector.

SC Engineering announced on the 13th that its cumulative consolidated sales for the third quarter reached 127.1 billion KRW, a 27% increase compared to the same period last year. Operating profit for the same period rose 799% year-on-year to 4.6 billion KRW, and net profit turned positive at 4.1 billion KRW.

The strong performance was driven by expanded revenue recognition based on a robust order backlog in the EPC segment, the company’s main business. Additionally, the rapid growth of the healthcare segment, a new business area, contributed to both top-line growth and improved profitability.

Up to the third quarter of this year, the company achieved new orders exceeding 250 billion KRW, more than double the size of last year’s EPC business. It significantly expanded its order base in advanced new growth industries such as hydrogen, secondary batteries, and specialty chemicals, setting a record high order volume within just three quarters.

The healthcare business, centered on the "SwitchOn Diet Program," saw a sharp rise in sales and profits, boosting overall performance. The company explained that strengthening online marketing through YouTube based on excellent product quality, along with expanding the health food lineup to improve customer accessibility, were key factors.

The continuous growth of subsidiary Cellontech also draws attention. Cellontech’s aggressive efforts to expand domestic and international sales channels for its unique bio-collagen-based intra-articular injection ‘Cartizol,’ cosmetic filler ‘TheraFill,’ and tendon/ligament reconstruction product ‘RegenSeal’ are showing tangible results.

In particular, since June, Cellontech has rapidly increased its growth by conducting joint marketing of Cartizol with leading domestic pharmaceutical companies such as LG Chem, Dongkook Pharmaceutical, and Kolon Pharmaceutical. Cellontech is also actively expanding overseas markets, having signed supply contracts with six companies across three countries, including China’s Sahuan Pharmaceutical, securing a minimum order quantity (MOQ) worth 120 billion KRW over the past year.

An SC Engineering official stated, “With the foundation for sustainable mid- to long-term growth in place, we expect to maintain strong performance not only this year but also next year. We will pursue both quantitative and qualitative growth simultaneously through efficient project management based on a solid order backlog and steady new orders.”

He added, “The healthcare business plans to establish itself as a stable profit source by expanding sales channels to strengthen experiential customer communication, following the successful entry into Olive Young in July. Our subsidiary Cellontech is expected to accelerate performance growth as overseas sales, led by the ASEAN market, begin in earnest next year, alongside ongoing efforts to strengthen domestic and international sales networks.”